title: Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms.
abstract: OBJECTIVE
  The polyphenol quercetin may prevent cardiovascular diseases due to its vasorelaxant and anti-oxidative properties. We investigated the effects of quercetin on risk factors of atherosclerosis, biomarkers of inflammation and oxidative stress, depending on the apolipoprotein E (APOE) genotype.
  
  
  RESULTS
  In a double-blind crossover study 49 healthy male subjects with APOE genotype 3/3 (n = 19), 3/4 (n = 22) and 4/4 (n = 8) consumed 150 mg/d quercetin or placebo for 8 weeks each, intermitted by a three-week washout phase. After each intervention, endothelial function, anthropometry, metabolic and inflammatory parameters were measured in the fasting and postprandial state following a standardized lipid-rich meal. Endothelial function was not changed. In all subjects combined, quercetin significantly decreased waist circumference (P = 0.004) and postprandial systolic blood pressure (P = 0.044). Postprandial triacylglycerol concentrations were significantly decreased and HDL-cholesterol concentrations increased after quercetin as compared to placebo consumption (P = 0.025). Quercetin also moderately increased levels of TNFα (P = 0.024). There was a significant gene-diet interaction for waist circumference and for body mass index (BMI).
  
  
  CONCLUSIONS
  Quercetin supplementation improved some risk factors of cardiovascular disease, yet exerted slightly pro-inflammatory effects. Genotype-dependent effects were seen only on waist circumference and BMI.
authors: Max Rubner-Institut, Federal Research Institute of Nutrition and Food, Department of Physiology and Biochemistry of Nutrition, Hermann-Weigmann-Str. 1, D-24103 Kiel, Germany. maria.pfeuffer@mri.bund.de
authors: M
authors: M
authors: Pfeuffer
authors: A
authors: A
authors: Auinger
authors: U
authors: U
authors: Bley
authors: I
authors: I
authors: Kraus-Stojanowic
authors: C
authors: C
authors: Laue
authors: P
authors: P
authors: Winkler
authors: C E
authors: CE
authors: Rüfer
authors: J
authors: J
authors: Frank
authors: C
authors: C
authors: Bösch-Saadatmandi
authors: G
authors: G
authors: Rimbach
authors: J
authors: J
authors: Schrezenmeir
mesh_terms: D000368:Aged; D000483:Alleles; D000886:Anthropometry; D000975:Antioxidants / Q000008:administration & dosage; D053318:Apolipoprotein E3 / Q000097:blood / Q000235:genetics*; D053327:Apolipoprotein E4 / Q000097:blood / Q000235:genetics*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D018592:Cross-Over Studies; D004032:Diet; D019587:Dietary Supplements; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D005215:Fasting; D005838:Genotype; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000517:prevention & control; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D010641:Phenotype; D059808:Polyphenols / Q000008:administration & dosage; D019518:Postprandial Period / Q000187:drug effects; D011446:Prospective Studies; D011794:Quercetin / Q000008:administration & dosage* / Q000097:blood; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000975:Antioxidants; D053318:Apolipoprotein E3; D053327:Apolipoprotein E4; D015415:Biomarkers; D008076:Cholesterol, HDL; D059808:Polyphenols; D014280:Triglycerides; D011794:Quercetin